Clinical Trial Update: A Study of Multiple Doses of HM15211(Efocipegtrutide) in Obese Subjects With NAFLD [Phase 1]

View source ↗

Summary

Phase 1 study evaluating multiple-dose Efocipegtrutide (HM15211) in obese subjects with non-alcoholic fatty liver disease has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Fatty Liver Disease
• Obesity

Drugs mentioned

• Efocipegtrutide (HM15211) (Efocipegtrutide)

Snippet

Sponsor: Hanmi Pharmaceutical Company Limited | Conditions: NAFLD | Phase 1 | Status: COMPLETED | Results posted: 2025-01-27